Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Urology

• Publication date

  2001-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(05)65822-3PMID 11547123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Her-2-neu expression and progression toward androgen independence in human prostate cancer.

  2000cited by this paper
• Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors.

  2000cited by this paper
• From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

  1999cited by this paper
• Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.

  1999cited by this paper
• Sensitivity and detection efficiency of a novel two-step detection system (PowerVision) for immunohistochemistry

  1999cited by this paper
• New pieces to the prostate cancer puzzle

  1999cited by this paper
• Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer.

  1999cited by this paper
• Treatment of prostate cancer

  1999cited by this paper
• Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.

  1999cited by this paper
• Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.

  1999cited by this paper
• Prognostic value of immunohistochemical expression of the c‐erbB‐2 oncoprotein in metastasic prostate cancer

  1999cited by this paper
• Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.

  1999cited by this paper
• A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase

  1999cited by this paper
• The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

  1998cited by this paper
• Over‐expression of epidermal growth factor receptor and c‐ erbB2/neu but not of int‐2 genes in benign prostatic hyperplasia by means of semi‐quantitative PCR

  1998cited by this paper
• HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.

  1998cited by this paper
• Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.

  1998cited by this paper
• Pathological changes in prostate lesions after androgen manipulation.

  1998cited by this paper
• Antigen Retrieval Immunohistochemistry: Past, Present, and Future

  1997cited by this paper
• Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.

  1997cited by this paper
• c‐erbB‐2 oncoprotein: A potential biomarker of advanced prostate cancer

  1997cited by this paper
• Prognostic significance of HER‐2/neu gene amplification status by fluorescence in Situ hybridization of prostate carcinoma

  1997cited by this paper
• Overexpression of her-2/neu in human prostate cancer and benign hyperplasia.

  1996cited by this paper
• The role of neoadjuvant androgen deprivation prior to radical prostatectomy.

  1996cited by this paper
• 101. Change in expression of epidermal growth factor receptor and c-erb-B2 during the development of tamoxifen resistance in human breast cancer

  1995cited by this paper
• Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines

  1992cited by this paper
• Tamoxifen up-regulates c-erbB-2 expression in oestrogen-responsive breast cancer cells in vitro.

  1992cited by this paper
• p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.

  1992cited by this paper
• Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas.

  1992cited by this paper
• Estrogen receptor variants in clinical breast cancer.

  1991cited by this paper
• HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer.

  1989cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Proto-oncogene amplification and human breast tumor phenotype.

  1989cited by this paper
• Adjuvant radiotherapy following radical prostatectomy: results and complications.

  1986cited by this paper
• Urologic pathology: The prostate

  1977cited by this paper
• A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen‐treated responsive and refractory human prostatic carcinoma

  1977cited by this paper

• Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics

  2024cites this paper
• The Association of ERG and c-erbB2 Expressions With Gleason Scoring in Adenocarcinomas of the Prostate

  2022cites this paper
• ZHER2 Affibody as a Good Candidate for Detection of Metastatic Prostate Cancer

  2021cites this paper
• Study of HER2/neu over Expression and Androgen Receptor Status in Prostate Neoplasm-Correlating with Histological Grading

  2021cites this paper
• Combined targeting of EGFR and HER2 against prostate cancer stem cells

  2020cites this paper
• Alterations of COX-2, HER-2/neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings.

  2019cites this paper
• Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer

  2019cites this paper
• Functional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion

  2017cites this paper
• A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer

  2017cites this paper
• Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.

  2017cites this paper
• ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer

  2016cites this paper
• Radioimmunotherapy for Prostate Cancer--Current Status and Future Possibilities.

  2016cites this paper
• Prognostic value of HER2/neu expression in patients with prostate cancer: a systematic review

  2015cites this paper
• Effect of siRNA targeting HER2/neu on the proliferation and viability of prostate cancer PC-3M cells.

  2015cites this paper
• Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment

  2014cites this paper
• Immunologic biomarkers in prostate cancer

  2014cites this paper
• Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study

  2014cites this paper
• The Biology of Aging and the Development of Lower Urinary Tract Dysfunction and Disease

  2014cites this paper
• AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial

  2013cites this paper
• Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: A possible radioimmunotherapy to prostate carcinoma

  2013cites this paper
• Hedgehog Signaling in Prostate Cancer and Its Therapeutic Implication

  2013cites this paper
• Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma

  2013cites this paper
• Profiling serum HER-2/NEU in prostate cancer.

  2013cites this paper
• A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors.

  2013cites this paper
• Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?

  2012cites this paper
• The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.

  2012cites this paper
• Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.

  2012cites this paper
• Cannabinoid Receptor 2: A Novel Multi-Targeted Approach in the Treatment of Breast Cancer and Related Skeletal Metastasis

  2012cites this paper
• prostate cancer cells stability in the transition of androgen requirement in The significance of Her2 on androgen receptor protein

  2011cites this paper
• Identification and Targeting of Upstream Tyrosine Kinases Mediating PI3 Kinase Activation in PTEN Deficient Prostate Cancer

  2011cites this paper
• The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.

  2011cites this paper
• To Die or to Survive, a Fatal Question for the Destiny of Prostate Cancer Cells after Androgen Deprivation Therapy

  2011cites this paper
• The significance of Her 2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells

  2011cites this paper
• Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells

  2011cites this paper
• Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer.

  2011cites this paper
• Matriptase is involved in ErbB-2-induced prostate cancer cell invasion.

  2010cites this paper
• Disruption of HER2 signalling by the monoclonal antibody trastuzumab or the tyrosine kinase inhibitor lapatinib improves survival of patients with metastatic breast

  2010cites this paper
• ‘Image and treat’: an individualized approach to urological tumors

  2010cites this paper
• Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

  2010cites this paper
• Prognostic significance of focal neuroendocrine differentiation in prostate cancer: Cases with autopsy-verified cause of death

  2010cites this paper
• Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination

  2010cites this paper
• New therapies for prostate cancer?

  2010cites this paper
• Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.

  2010cites this paper
• A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue

  2010cites this paper
• Tumorigenesis and Neoplastic Progression Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion

  2010cites this paper
• The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression

  2009cites this paper
• Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.

  2009cites this paper
• LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion.

  2009cites this paper
• Can Androgen Receptor Expression in Prostate Cancer Cells Is Suppressed by Activation of Epidermal Growth Factor Receptor and ErbB 2

  2009cites this paper
• Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties.

  2009cites this paper
• Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer

  2009cites this paper
• Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

  2009cites this paper
• Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.

  2009cites this paper
• Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.

  2008cites this paper
• Demystifying the ABU (and interpreting the alphabet soup of acronyms associated with it).

  2008cites this paper
• Elevated levels of HER‐2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential

  2008cites this paper
• Morphological changes induced by androgen blockade in normal prostate and prostatic carcinoma.

  2008cites this paper
• Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling

  2008cites this paper
• The Role of EGFR, HER 2-4, Heregulin and Downstream Signalling in Prostate Adenocarcinoma

  2008cites this paper
• Characterisation of a dominant negative androgen receptor in prostate cancer cells.

  2008cites this paper
• Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer

  2008cites this paper
• Autoantibody Biomarkers in Prostate Cancer

  2008cites this paper
• Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?

  2008cites this paper
• Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy.

  2008cites this paper
• [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].

  2008cites this paper
• Role of Epidermal Growth Factor Receptor and the HER-2 Gene in Hormone Refractory Prostate Cancer

  2008influential citation
• Molekular getriggerte Therapie des hormonrefraktären Prostatakarzinoms

  2008cites this paper
• Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer

  2007cites this paper
• ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.

  2007cites this paper
• Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms

  2007cites this paper
• Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer.

  2007cites this paper
• Pathogenesis of prostate cancer and hormone refractory prostate cancer

  2007cites this paper
• Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

  2007cites this paper
• Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

  2007cites this paper
• [Prostatic cancers].

  2007cites this paper
• Cancer de la prostate

  2007cites this paper
• Tetracycline Regulated Systems in Functional Oncogenomics

  2006cites this paper
• Mithramycin Targets Sp1 and The Androgen Receptor Transcription Level—Potential Therapeutic Role in Advanced Prostate Cancer

  2006cites this paper
• HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.

  2006influential citation
• Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy

  2006cites this paper
• Hsp90: A Target for Prostate Cancer Therapy

  2006cites this paper
• Novel HER2 selective tyrosine kinase inhibitor, TAK‐165, inhibits bladder, kidney and androgen‐independent prostate cancer in vitro and in vivo

  2006cites this paper
• Androgen-dependent regulation of Her-2/neu in prostate cancer cells.

  2006cites this paper
• Androgen-dependent regulation of Her-2/neu in prostate cancer cells.

  2006cites this paper
• Amplification and Overexpression of ERBB2, uPA, TRPS1, EIF3S3 and MYC Genes in Prostate Cancer

  2006cites this paper
• Role of coordinated molecular alterations in the development of androgen‐independent prostate cancer: an in vitro model that corroborates clinical observations

  2006cites this paper
• Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.

  2006cites this paper
• Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.

  2006cites this paper
• Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells

  2006cites this paper
• Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.

  2005cites this paper
• Protein-embedding Technique: A Potential Approach to Standardization of Immunohistochemistry for Formalin-fixed, Paraffin-embedded Tissue Sections

  2005cites this paper
• Her2/neu Expression by Reverse Transcriptase-Polymerase Chain Reaction in the Peripheral Blood of Prostate Cancer Patients

  2005cites this paper
• Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer

  2005cites this paper
• Mechanisms responsible for ERBB2 gene overexpression in human breast and non-breast cancer cells. The role of AP-2 transcription factors

  2005cites this paper
• Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth

  2005cites this paper
• Die Behandlung des hormonrefraktären Prostatakarzinoms - neue Standards, neue Trends

  2005cites this paper
• [Therapy of hormone refractory prostate cancer: new standards, new trends].

  2005cites this paper
• Mechanisms of the development of androgen independence in prostate cancer

  2005cites this paper
• Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.

  2005cites this paper
• ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells

  2005cites this paper